Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

Click for more information

3.57%

14.5¢ resapp health limited

Ann: ResApp Provides SMARTCOUGH-C-2 Study Update, page-56

First 56 Last

Share
Profile

Follow
Limitless

49 Posts.

2

13/03/18

00:40

Post #: 31701544
Share

Originally posted by Limitless ↑

This is a confident step forward for the company and it does bode well for an optimistic medium to long-term outlook, however, in all honesty, there is a board of directors and a CEO that could well and truly have much these responsibilities under their remit, namely Nathan Buzza who was appointed recently and ticks a majority of the requirements.

He is constantly posting away about Alcidion on Twitter, yet was silent on what was a fairly significant announcement recently to boost SH confidence in the company and the pending US trials. Do better ResApp. He is no longer a director of Alcidion, he is, however, a director of ResApp.

Expand

In reference to the position description/advertisement "Business Development and Partnerships Manager"

RAP Price at posting: 12.5¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

First 56 Last

Add RAP (ASX) to my watchlist